ONCORUS INC (ONCR)       0.4801  -0.13 (-21.53%)

0.4801  -0.13 (-21.53%)

US68236R1032 - Common Stock - After market: 0.5041 +0.02 (+5%)


Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ONCR. ONCR was compared to 631 industry peers in the Biotechnology industry. Both the profitability and financial health of ONCR have multiple concerns. ONCR has a expensive valuation and it also scores bad on growth




Profitability

Profitability Rating

1

ONCR's Return On Assets of -46.44% is in line with the rest of the industry. The industry average Return On Assets is -44.83%.
ONCR has negative profitability rations, so we won't be analyzing them here.

ONCR has a very weak Piotroski-F score of 2.00. This is an indication of health and profitability issues for ONCR.
VS Industry

ROA (-46.44%) VS Industry: 48% outperformed.

-950.38
52.28

Valuation

Valuation Rating

3

When comparing the current price to the book value of ONCR, it is valued rather cheaply. It is trading at 0.16 times its book value.
When comparing the price book ratio of ONCR to the average industry price book ratio of 1.71, ONCR is valued rather cheaply. ONCR is also cheaper than 99% of the companies listed in the same industry.
When comparing the Enterprise Value to EBITDA ratio of ONCR to the average industry ratio of 1.07, ONCR is valued in line with its industry peers.

ONCR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ONCR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
VS Industry

Price/Book (0.16) VS Industry: 99% outperformed.

127.24
0.10

Enterprise Value/ EBITDA (1.18) VS Industry: 46% outperformed.

3,469.94
0.01

Growth

Growth Rating

1

Based on estimates for the next 5 years, ONCR will show a small growth in Earnings Per Share. The EPS will grow by 0.05% on average per year.

The earnings per share for ONCR have decreased strongly by -26.50% in the last year.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPSN/A N/A -26.5% -11.07% 10.27% 8.43% 0.05%
RevenueN/A N/A N/A N/A N/A N/A N/A

Health

Health Rating

2

ONCR has a Current Ratio of 4.97. This indicates that ONCR is financially healthy and has no problem in meeting its short term obligations.
A Quick Ratio of 4.97 indicates that ONCR has no problem at all paying its short term obligations.
ONCR has a Current Ratio comparable to the industry average, which is at 6.16.
The Quick Ratio is in line with the industry averages, which is at 6.05.

ONCR has one of the worst Debt to Equity ratios in its industry. 83% of its industry peers require less debt for financing their operations.
ONCR has an Altman-Z score of -3.06. This is a bad value and indicates that ONCR is not financially healthy and even has some risk of bankruptcy.
Compared to an average industry Altman-Z score of -0.81, ONCR is in worse financial health than its industry peers.
The Piotroski-F score of ONCR is 2.00. This is a very weak score and indicates problems in health and profitability for ONCR.
VS Industry

Debt/Equity (0.24) VS Industry: 17% outperformed.

15.37
0.00

Quick Ratio (4.97) VS Industry: 41% outperformed.

0.02
84.53

Current Ratio (4.97) VS Industry: 41% outperformed.

0.02
85.09

Altman-Z (-3.06) VS Industry: 38% outperformed.

-135.10
443.02

Dividend

Dividend Rating

0

No dividends for ONCR!.

ONCR Daily chart

ONCORUS INC0.4801

NASDAQ:ONCR (11/30/2022, 7:00:02 PM)-0.13 (-21.53%)

After market: 0.5041 +0.02 (+5%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry Biotechnology
Earnings (Last) 11-02 2022-11-02/bmo Earnings (Next) 03-07 2023-03-07
Ins Owners 0.64% Inst Owners 63.93%
Market Cap 12.47M Analysts 82
Valuation
PE N/A Fwd PE N/A
PEG (NY) N/A PEG (5Y) N/A
P/S N/A P/B 0.16
EV/EBITDA 1.18
Dividend
Dividend Yield N/A Dividend Growth N/A
DP N/A Ex-Date N/A
Growth
EPS 1Y -26.5% EPS 3Y N/A
EPS 5Y N/A EPS growth Q2Q -16.92%
EPS Next Y -11.07% EPS Next 2Y 10.27%
EPS Next 3Y 8.43% EPS Next 5Y 0.05%
Revenue growth 1Y N/A Revenue growth 3Y N/A
Revenue growth 5Y N/A Revenue growth Q2Q N/A
Revenue Next Year N/A Revenue Next 2Y N/A
Revenue Next 3Y N/A Revenue Next 5Y N/A
Health
Current Ratio 4.97 Quick Ratio 4.97
Altman-Z -3.06 F-Score 2
Debt/Equity 0.24 WACC N/A
ROIC/WACC N/A
Profitability
ROA -46.44% ROE N/A
ROICexgc N/A ROIC N/A
PM N/A OM N/A
Asset Turnover N/A

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA